Clinical Research Directory

The study population can be viewed from the cluster (clinic), clinician, staff, or patient level. At the cluster (clinic) level: To be eligible to participate in this study, a cluster (clinic) must meet all the following criteria: 1. Active participation in the St. Louis Integrated Health Center Network for Community Academic Partnerships. 2. Employment of at least 3 clinicians who commonly manage adult asthma (defined as managing asthma for at least one adult asthma patient, on average, on a weekly basis). 3. Data provided to Azara for data queries, and 4. Willing and able to receive all components of the SMART implementation bundle (i.e., initial educational outreach visit, ongoing practice facilitation/supervision, audit \& feedback, and provision of education of patient-level education aides and SMART asthma action plans and monthly operations committee meetings). At the clinician/clinical staff level: To be eligible to participate in this study, a clinician/clinical staff member must meet all of the following criteria: 1. Provision of a signed and dated informed consent form. 2. Current state licenses of physician, assistant physician, nurse practitioner, or physician assistant. 3. Regularly cares for adults with asthma (which may include those trained in family medicine, internal medicine, obstetrics/gynecology, and/or specialty medicine). 4. Willing and able to integrate the SMART implementation bundle into their practice. 5. Willing and able to participate for the entire duration of the study, including the pre-implementation, active implementation, and post-implementation periods. 6. Willing to provide data on prescribing patterns and asthma patient outcomes for the duration of the study. At the patient level: To be eligible to participate in this study, a patient must meet all of the following criteria: 1. Age ≥12 years old 2. Diagnosis of asthma, of any severity, coded (i.e., International Classification of Diseases \[ICD\]-10-CM: J45\*\*). 3. The patient has had ≥2 asthma exacerbations in the last year during which systemic corticosteroids were prescribed, and/or the encounter contains an active prescription for an inhaler that is congruent with medium-dose (or higher) maintenance inhaled corticosteroids (ICS) inhalers or low-dose (or higher) ICS-long-acting β-agonist (LABA) inhalers with concomitant reliever short-acting β-agonist inhalers.